{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:26:02Z","timestamp":1790220362896,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Epcoritamab is a subcutaneously administered CD3xCD20 bispecific Ab that showed deep, durable responses with a manageable safety profile in patients with relapsed or refractory (R\/R) diffuse large B\u2010cell lymphoma (DLBCL) in the global multicenter pivotal phase II trial EPCORE NHL\u20101. Here, we present results from the similar EPCORE NHL\u20103 phase I\/II trial evaluating epcoritamab monotherapy in Japanese patients with R\/R CD20<jats:sup>+<\/jats:sup> B\u2010cell non\u2010Hodgkin's lymphoma previously treated with two or more lines of therapy. Epcoritamab was dosed subcutaneously in 28\u2010day cycles; once weekly during cycles 1\u20133, every 2\u2009weeks during cycles 4\u20139, and every 4\u2009weeks from cycle 10 until disease progression or unacceptable toxicity. Step\u2010up dosing and cytokine release syndrome (CRS) prophylaxis were used during treatment cycle 1. As of January 31, 2022, 36 patients received treatment with 48\u2009mg epcoritamab monotherapy. At a median follow\u2010up of 8.4\u2009months, overall response and complete response rates by independent review committee were 55.6% and 44.4%, respectively. The median duration of response, duration of complete response, and overall survival were not reached at the time of data cut\u2010off. The most common treatment\u2010emergent adverse events of any grade were CRS (83.3%), injection\u2010site reactions (69.4%), infections (44.4%), neutropenia (38.9%), hypokalemia (27.8%), and decreased lymphocyte count (25.0%). Cytokine release syndrome occurrence was predictable; events were primarily low grade (grade 1\u20132), all resolved, and none led to treatment discontinuation. These encouraging results are consistent with previous findings and support the ongoing clinical evaluation of epcoritamab for the treatment of R\/R DLBCL, including in earlier treatment lines.<\/jats:p>","DOI":"10.1111\/cas.15996","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T11:59:21Z","timestamp":1699012761000},"page":"4643-4653","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large <scp>B\u2010cell<\/scp> lymphoma"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":false,"given":"Koji","family":"Izutsu","sequence":"first","affiliation":[{"name":"Department of Hematology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kumode","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology Kindai University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Yuda","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Experimental Therapeutics, Office for the Promotion of Hematological Treatment Development National Cancer Center Hospital East  Kashiwa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Nagoya Medical Center  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9742-8470","authenticated-orcid":false,"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Japanese Foundation for Cancer Research Cancer Institute Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy National Hospital Organization Kyushu Cancer Center  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy Aichi Cancer Center  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Fujisaki","sequence":"additional","affiliation":[{"name":"Department of Hematology Japan Red Cross Society, Matsuyama Red Cross Hospital  Matsuyama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7030-497X","authenticated-orcid":false,"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology Kagoshima University  Kagoshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine Yamagata University  Yamagata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[{"name":"Department of Hematology Fukushima Medical University Hospital  Fukushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-2162","authenticated-orcid":false,"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine Kyoto University  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Akahane","sequence":"additional","affiliation":[{"name":"Department of Hematology Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Graduate School of Medicine Osaka University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Dinh","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development AbbVie  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Soong","sequence":"additional","affiliation":[{"name":"Translational Data Science Genmab  Plainsboro New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Biostatistics Genmab  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe Klint","family":"Buchbjerg","sequence":"additional","affiliation":[{"name":"Clinical Research Scientists Genmab  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Favaro","sequence":"additional","affiliation":[{"name":"Medical Hematology Genmab  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Hematology Tohoku University  Sendai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1805"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2430-6"},{"key":"e_1_2_11_4_1","unstructured":"B\u2010Cell Non\u2010Hodgkin's Lymphoma (NHL).Opportunity Analysis and Forecasts to 2027.2019GlobalData Accessed September 6 2023. Available at:https:\/\/www.globaldata.com\/store\/report\/b\u2010cell\u2010non\u2010hodgkins\u2010lymphoma\u2010nhl\u2010opportunity\u2010analysis\u2010and\u2010forecasts\u2010to\u20102027\/"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31366-0"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14937"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13239"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002056"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.11.011"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01725"},{"key":"e_1_2_11_18_1","volume-title":"Epkinly [Package Insert]","year":"2023"},{"key":"e_1_2_11_19_1","unstructured":"Epkinly [Package Insert]. Genmab K.K.; 2023."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635169"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01618-w"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0177"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.335"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.15996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T20:00:15Z","timestamp":1704484815000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.15996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/cas.15996"],"URL":"https:\/\/doi.org\/10.1111\/cas.15996","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"2023-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}